Screener
Palvella Therapeutics PVLA Other Income (Expense)
Other Income (Expense) at other companies
Other financials
Where this comes from
Reported directly by Palvella Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OtherNonoperatingIncomeExpense.
The source filing: Palvella Therapeutics’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 8:30 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-210463
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Fair value adjustments on derivative liabilities – royalty agreement | (116) | (75) |
| Fair value adjustments on derivative liabilities – contingent value right liability | 202 | — |
| Interest income, net | 1,073 | 752 |
| Other income (expense), net | (32) | 224 |
| Loss before income taxes | (15,767) | (8,185) |
| Income tax benefit (expense) | — | — |
| Net loss | $(15,767) | $(8,185) |
| Other comprehensive loss: |
Item 1. Financial Statements.
FAQ
- What is Palvella Therapeutics's other income (expense)?
- Palvella Therapeutics (PVLA) reported other income (expense) of -$32K in Q1 2026.
- How has Palvella Therapeutics's other income (expense) changed year-over-year?
- Palvella Therapeutics's other income (expense) decreased by 114.3% year-over-year, from $224K to -$32K.
- What does other income (expense) mean?
- Net total of all non-operating income and expenses not classified in specific line items — a catch-all for miscellaneous financial items.
Ask your AI about Palvella Therapeutics's other income (expense).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude